Independent mortality predictors in older COVID-19 patients with delayed hospitalization: A retrospective study from Eastern China, 2023
et al., Medicine, doi:10.1097/MD.0000000000049099, May 2026
Retrospective 300 elderly hospitalized COVID-19 patients in China, showing no mortality benefit with antivirals (paxlovid and molnupiravir) in multivariable analysis, OR 1.15 [0.28-4.74], without statistical significance.
Potential risks of molnupiravir include the creation of dangerous variants, and mutagenicity, carcinogenicity, teratogenicity, and embryotoxicity1-15. Multiple analyses have identified variants potentially created by molnupiravir16-20. Studies show significantly increased risk of acute kidney injury21, cardiovascular toxocity22, and neurological symptoms21. Treatment may increase viral rebound23,24.
Study covers molnupiravir and paxlovid.
1.
Swanstrom et al., Lethal mutagenesis as an antiviral strategy, Science, doi:10.1126/science.abn0048.
2.
Hadj Hassine et al., Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity, Viruses, doi:10.3390/v14040841.
3.
Shum, C., An investigational study into the drug-associated mutational signature in SARS-CoV-2 viruses, The University of Hong Kong, PhD Thesis, hub.hku.hk/handle/10722/344396.
4.
Waters et al., Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: the special case of molnupiravir, Environmental and Molecular Mutagenesis, doi:10.1002/em.22471.
5.
Huntsman, M., An assessment of the reproductive toxicity of the anti-COVID-19 drug molnupiravir using stem cell-based embryo models, Master's Thesis, scholarspace.manoa.hawaii.edu/items/cd11342c-b4dc-44c0-8b44-ce6e3369c40b.
6.
Huntsman (B) et al., Detection of developmental toxicity of the anti-COVID-19 drug molnupiravir using gastruloid-based in vitro assays, Toxicological Sciences, doi:10.1093/toxsci/kfaf093.
7.
Zibat et al., N4-hydroxycytidine, the active compound of Molnupiravir, promotes SARS-CoV-2 mutagenesis and escape from a neutralizing nanobody, iScience, doi:10.1016/j.isci.2023.107786.
8.
Shiraki et al., Convenient screening of the reproductive toxicity of favipiravir and antiviral drugs in Caenorhabditis elegans, Heliyon, doi:10.1016/j.heliyon.2024.e35331.
9.
Gruber et al., Molnupiravir increases SARS‐CoV‐2 genome diversity and complexity: A case‐control cohort study, Journal of Medical Virology, doi:10.1002/jmv.29642.
10.
Marikawa et al., An active metabolite of the anti-COVID-19 drug molnupiravir impairs mouse preimplantation embryos at clinically relevant concentrations, Reproductive Toxicology, doi:10.1016/j.reprotox.2023.108475.
11.
Rahman, M., Elucidation of the DNA repair mechanisms involved in the repair of DNA damage caused by the Arabinosides and Anti-COVID-19 drugs, tokyo-metro-u.repo.nii.ac.jp/records/2000972.
12.
Zhou et al., β-D-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells, The Journal of Infectious Diseases, doi:10.1093/infdis/jiab247.
13.
Chamod et al., Molnupiravir Metabolite--N4-hydroxycytidine Causes Cytotoxicity and DNA Damage in Mammalian Cells in vitro: N4-hydroxycytidine Induced Cytotoxicity DNA Damage, Asian Medical Journal and Alternative Medicine, 23:3, asianmedjam.com/index.php/amjam/article/view/1448.
14.
Standing et al., Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients, Nature Communications, doi:10.1038/s41467-024-45641-0.
15.
Mori et al., Reactive oxygen species-mediated cytotoxic and DNA-damaging mechanism of N4-hydroxycytidine, a metabolite of the COVID-19 therapeutic drug molnupiravir, Free Radical Research, doi:10.1080/10715762.2025.2469738.
16.
Focosi et al., The fitness of molnupiravir-signed SARS-CoV-2 variants: imputation analysis based on prescription counts and GISAID analyses by country, Intervirology, doi:10.1159/000540282.
17.
Sanderson et al., A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes, Nature, doi:10.1038/s41586-023-06649-6.
18.
Fountain-Jones et al., Effect of molnupiravir on SARS-CoV-2 evolution in immunocompromised patients: a retrospective observational study, The Lancet Microbe, doi:10.1016/S2666-5247(23)00393-2.
19.
Kosakovsky Pond et al., Anti-COVID drug accelerates viral evolution, Nature, doi:10.1038/d41586-023-03248-3.
21.
Siby et al., Temporal Trends in Serious Adverse Events Associated with Oral Antivirals During the COVID-19 Pandemic: Insights from the FAERS Database (2020–2023), Open Forum Infectious Diseases, doi:10.1093/ofid/ofaf695.1825.
22.
Ozhan et al., Evaluation of the cardiopulmonary effects of repurposed COVID-19 therapeutics in healthy rats, Scientific Reports, doi:10.1038/s41598-025-31048-4.
Liu et al., 29 May 2026, retrospective, China, peer-reviewed, median age 82.0, 6 authors, study period 8 December, 2022 - 12 January, 2023.
Contact: mhf1988@126.com.
Abstract: ®
Independent mortality predictors in older COVID19 patients with delayed hospitalization A retrospective study from Eastern China, 2023
Qiaoli Liu, MD a , Lifu Zhao, MD a , Mei Li, MD a , Chunwei Shi, MD a , Piao Hu, MD a , Haifeng Miao, MD a, *
Abstract
Delayed hospitalization of older patients with COVID-19 results in the loss of the early antiviral treatment window, as well as the progression to critical illness involving shock, hypoxemia, and corticosteroid therapy. Nevertheless, the hierarchy of independent mortality predictors in this specific context remains to be fully established. The study aimed to identify and rank these predictors to inform clinical management. This retrospective observational study was conducted at the First People's Hospital of Xiaoshan District, China (January-February 2023). The present study included hospitalized patients aged ≥ 60 years with first-time severe acute respiratory syndrome coronavirus-2 infection and delayed hospitalization (>5 days from symptom onset). The data were predominantly collected electronically. Univariate and multivariate logistic regression were performed to identify independent risk factors for mortality. A total of 300 older hospitalized COVID-19 patients (median age 82 years; 57.3% male) were included. Overall mortality was 17.3% (52/300). In multivariable logistic regression, independent factors associated with mortality included older age (OR: 1.11, 95% CI: 1.03-1.19), elevated cardiac troponin I (OR: 1.01, 95% CI: 1.0-1.02), presence of shock (OR: 26.72, 95% CI: 7.27-98.18), prolonged corticosteroid use (OR: 8.19, 95% CI: 2.39-28.05), and requirement of oxygen therapy for hypoxia (OR: 2.98, 95% CI: 1.70-5.23). Shock was the strongest independent predictor of mortality in older COVID-19 patients with delayed hospitalization, outweighing prolonged corticosteroid use and hypoxemia. These findings emphasize the critical importance of early shock recognition in this vulnerable population, while also highlighting the need for judicious corticosteroid use. The identified risk hierarchy may serve as a framework for clinical decision-making in resource-constrained settings.
Abbreviations: ALT = alanine aminotransferase, BUN = blood urea nitrogen, CI = confidence interval, COVID-19 = coronavirus disease 2019, CRP = C-reactive protein, Hb = hemoglobin, IMV = invasive mechanical ventilation, L = lymphocyte, OR = odds Ratio, PLT = platelet, RCT = randomized controlled trial, SARS-CoV-2 = severe acute respiratory syndrome coronavirus-2, SCR = serum creatinine, WBC = white blood cell.
Keywords: COVID-19, delayed hospitalization, mortality, older, SARS-CoV-2
DOI record:
{
"DOI": "10.1097/md.0000000000049099",
"ISSN": [
"0025-7974",
"1536-5964"
],
"URL": "http://dx.doi.org/10.1097/MD.0000000000049099",
"abstract": "<jats:sec>\n <jats:title/>\n <jats:p>Delayed hospitalization of older patients with COVID-19 results in the loss of the early antiviral treatment window, as well as the progression to critical illness involving shock, hypoxemia, and corticosteroid therapy. Nevertheless, the hierarchy of independent mortality predictors in this specific context remains to be fully established. The study aimed to identify and rank these predictors to inform clinical management. This retrospective observational study was conducted at the First People’s Hospital of Xiaoshan District, China (January–February 2023). The present study included hospitalized patients aged ≥ 60 years with first-time severe acute respiratory syndrome coronavirus-2 infection and delayed hospitalization (>5 days from symptom onset). The data were predominantly collected electronically. Univariate and multivariate logistic regression were performed to identify independent risk factors for mortality. A total of 300 older hospitalized COVID-19 patients (median age 82 years; 57.3% male) were included. Overall mortality was 17.3% (52/300). In multivariable logistic regression, independent factors associated with mortality included older age (OR: 1.11, 95% CI: 1.03–1.19), elevated cardiac troponin I (OR: 1.01, 95% CI: 1.0–1.02), presence of shock (OR: 26.72, 95% CI: 7.27–98.18), prolonged corticosteroid use (OR: 8.19, 95% CI: 2.39–28.05), and requirement of oxygen therapy for hypoxia (OR: 2.98, 95% CI: 1.70–5.23). Shock was the strongest independent predictor of mortality in older COVID-19 patients with delayed hospitalization, outweighing prolonged corticosteroid use and hypoxemia. These findings emphasize the critical importance of early shock recognition in this vulnerable population, while also highlighting the need for judicious corticosteroid use. The identified risk hierarchy may serve as a framework for clinical decision-making in resource-constrained settings.</jats:p>\n </jats:sec>",
"assertion": [
{
"group": {
"label": "Publication History",
"name": "publication_history"
},
"label": "Received",
"name": "received",
"value": "2024-05-29"
},
{
"group": {
"label": "Publication History",
"name": "publication_history"
},
"label": "Accepted",
"name": "accepted",
"value": "2026-04-21"
}
],
"author": [
{
"affiliation": [
{
"name": "Department of Infectious Diseases, The First People’s Hospital of Xiaoshan District, Hangzhou, Zhejiang, China."
}
],
"family": "Liu",
"given": "Qiaoli",
"role": [
{
"role": "author",
"vocabulary": "crossref"
}
],
"sequence": "first"
},
{
"affiliation": [
{
"name": "Department of Infectious Diseases, The First People’s Hospital of Xiaoshan District, Hangzhou, Zhejiang, China."
}
],
"family": "Zhao",
"given": "Lifu",
"role": [
{
"role": "author",
"vocabulary": "crossref"
}
],
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Infectious Diseases, The First People’s Hospital of Xiaoshan District, Hangzhou, Zhejiang, China."
}
],
"family": "Li",
"given": "Mei",
"role": [
{
"role": "author",
"vocabulary": "crossref"
}
],
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Infectious Diseases, The First People’s Hospital of Xiaoshan District, Hangzhou, Zhejiang, China."
}
],
"family": "Shi",
"given": "Chunwei",
"role": [
{
"role": "author",
"vocabulary": "crossref"
}
],
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Infectious Diseases, The First People’s Hospital of Xiaoshan District, Hangzhou, Zhejiang, China."
}
],
"family": "Hu",
"given": "Piao",
"role": [
{
"role": "author",
"vocabulary": "crossref"
}
],
"sequence": "additional"
},
{
"ORCID": "https://orcid.org/0000-0002-8938-8333",
"affiliation": [
{
"name": "Department of Infectious Diseases, The First People’s Hospital of Xiaoshan District, Hangzhou, Zhejiang, China."
}
],
"authenticated-orcid": false,
"family": "Miao",
"given": "Haifeng",
"role": [
{
"role": "author",
"vocabulary": "crossref"
}
],
"sequence": "additional"
}
],
"container-title": "Medicine",
"content-domain": {
"crossmark-restriction": true,
"domain": [
"lww.com",
"ovid.com"
]
},
"created": {
"date-parts": [
[
2026,
5,
29
]
],
"date-time": "2026-05-29T17:05:13Z",
"timestamp": 1780074313000
},
"deposited": {
"date-parts": [
[
2026,
5,
29
]
],
"date-time": "2026-05-29T17:05:18Z",
"timestamp": 1780074318000
},
"indexed": {
"date-parts": [
[
2026,
5,
29
]
],
"date-time": "2026-05-29T18:02:28Z",
"timestamp": 1780077748206,
"version": "3.54.0"
},
"is-referenced-by-count": 0,
"issue": "22",
"issued": {
"date-parts": [
[
2026,
5,
29
]
]
},
"journal-issue": {
"issue": "22",
"published-print": {
"date-parts": [
[
2026
]
]
}
},
"language": "en",
"license": [
{
"URL": "http://creativecommons.org/licenses/by-nc/4.0/",
"content-version": "unspecified",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2026,
5,
29
]
],
"date-time": "2026-05-29T00:00:00Z",
"timestamp": 1780012800000
}
}
],
"link": [
{
"URL": "https://journals.lww.com/10.1097/MD.0000000000049099",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "276",
"original-title": [],
"page": "e49099",
"prefix": "10.1097",
"published": {
"date-parts": [
[
2026,
5,
29
]
]
},
"published-print": {
"date-parts": [
[
2026,
5,
29
]
]
},
"publisher": "Ovid Technologies (Wolters Kluwer Health)",
"reference": [
{
"DOI": "10.1016/S1473-3099(20)30120-1",
"article-title": "An interactive web-based dashboard to track COVID-19 in real time.",
"author": "Dong",
"doi-asserted-by": "crossref",
"first-page": "533",
"journal-title": "Lancet Infect Dis",
"key": "R1-20260529",
"volume": "20",
"year": "2020"
},
{
"DOI": "10.1016/j.jinf.2022.08.001",
"article-title": "Clinical features and outcomes of hospitalized patients with COVID-19 during the Omicron wave in Shanghai, China.",
"author": "Wang",
"doi-asserted-by": "crossref",
"first-page": "e27",
"journal-title": "J Infect",
"key": "R3-20260529",
"volume": "86",
"year": "2023"
},
{
"DOI": "10.1056/NEJMoa2001316",
"article-title": "Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia.",
"author": "Li",
"doi-asserted-by": "crossref",
"first-page": "1199",
"journal-title": "N Engl J Med",
"key": "R4-20260529",
"volume": "382",
"year": "2020"
},
{
"DOI": "10.1016/j.jinf.2020.02.018",
"article-title": "Characteristics of COVID-19 infection in Beijing.",
"author": "Tian",
"doi-asserted-by": "crossref",
"first-page": "401",
"journal-title": "J Infect",
"key": "R5-20260529",
"volume": "80",
"year": "2020"
},
{
"DOI": "10.1001/jamainternmed.2020.0994",
"article-title": "Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China.",
"author": "Wu",
"doi-asserted-by": "crossref",
"first-page": "934",
"journal-title": "JAMA Int Med",
"key": "R6-20260529",
"volume": "180",
"year": "2020"
},
{
"DOI": "10.1111/jgs.18163",
"article-title": "Clinical presentation of COVID-19 and association with outcomes among hospitalized older adults.",
"author": "Ohuabunwa",
"doi-asserted-by": "crossref",
"first-page": "599",
"journal-title": "J Am Geriatr Soc",
"key": "R7-20260529",
"volume": "71",
"year": "2023"
},
{
"DOI": "10.3390/geriatrics6010025",
"article-title": "COVID-19 infection among older people admitted to hospital: a cross-sectional analysis.",
"author": "Thiam",
"doi-asserted-by": "crossref",
"first-page": "25",
"journal-title": "Geriatrics (Basel)",
"key": "R8-20260529",
"volume": "6",
"year": "2021"
},
{
"DOI": "10.18632/aging.102988",
"article-title": "Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections.",
"author": "Zhavoronkov",
"doi-asserted-by": "crossref",
"first-page": "6492",
"journal-title": "Aging (Milano)",
"key": "R9-20260529",
"volume": "12",
"year": "2020"
},
{
"article-title": "Expert consensus on diagnosis and treatment of novel coronavirus infection in the elderly in China (primary care version) [in Chinese].",
"author": "Qi",
"first-page": "371",
"journal-title": "Chin J Geriatr",
"key": "R10-20260529",
"volume": "42",
"year": "2023"
},
{
"DOI": "10.1016/S0140-6736(22)01586-0",
"article-title": "Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.",
"author": "Wong",
"doi-asserted-by": "crossref",
"first-page": "1213",
"journal-title": "Lancet (Lond)",
"key": "R11-20260529",
"volume": "400",
"year": "2022"
},
{
"DOI": "10.1016/j.jinf.2023.02.029",
"article-title": "Molnupiravir and nirmatrelvir-ritonavir reduce mortality risk during post-acute COVID-19 phase.",
"author": "Wan",
"doi-asserted-by": "crossref",
"first-page": "622",
"journal-title": "J Infect",
"key": "R12-20260529",
"volume": "86",
"year": "2023"
},
{
"DOI": "10.3390/vaccines10101731",
"article-title": "Nirmatrelvir/ritonavir and molnupiravir in the treatment of mild/moderate COVID-19: results of a real-life study.",
"author": "Gentile",
"doi-asserted-by": "crossref",
"first-page": "1731",
"journal-title": "Vaccines (Basel)",
"key": "R13-20260529",
"volume": "10",
"year": "2022"
},
{
"DOI": "10.1016/S0140-6736(20)30566-3",
"article-title": "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.",
"author": "Zhou",
"doi-asserted-by": "crossref",
"first-page": "1054",
"journal-title": "Lancet (Lond)",
"key": "R14-20260529",
"volume": "395",
"year": "2020"
},
{
"DOI": "10.1093/ije/dyad012",
"article-title": "Characteristics and outcomes of an international cohort of 600 000 hospitalized patients with COVID-19.",
"author": "Kartsonaki",
"doi-asserted-by": "crossref",
"first-page": "355",
"journal-title": "Int J Epidemiol",
"key": "R15-20260529",
"volume": "52",
"year": "2023"
},
{
"DOI": "10.1136/bmjgh-2021-006434",
"article-title": "The isolated effect of age on the risk of COVID-19 severe outcomes: a systematic review with meta-analysis.",
"author": "Romero Starke",
"doi-asserted-by": "crossref",
"first-page": "e006434",
"journal-title": "BMJ Glob Health",
"key": "R16-20260529",
"volume": "6",
"year": "2021"
},
{
"DOI": "10.1038/s41598-023-37709-6",
"article-title": "The impact of comorbidities and COVID-19 on the evolution of community onset sepsis.",
"author": "de Araújo",
"doi-asserted-by": "crossref",
"first-page": "10589",
"journal-title": "Sci Rep",
"key": "R17-20260529",
"volume": "13",
"year": "2023"
},
{
"DOI": "10.1016/S2213-2600(20)30316-7",
"article-title": "Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study.",
"author": "Karagiannidis",
"doi-asserted-by": "crossref",
"first-page": "853",
"journal-title": "Lancet Respir Med",
"key": "R18-20260529",
"volume": "8",
"year": "2020"
},
{
"DOI": "10.1038/s41392-021-00521-7",
"article-title": "Efficacy and safety of systematic corticosteroids among severe COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials.",
"author": "Ma",
"doi-asserted-by": "crossref",
"first-page": "83",
"journal-title": "Signal Transduct Targeted Ther",
"key": "R19-20260529",
"volume": "6",
"year": "2021"
},
{
"DOI": "10.1186/s12879-022-07750-3",
"article-title": "Real-world effectiveness of steroids in severe COVID-19: a retrospective cohort study.",
"author": "Wang",
"doi-asserted-by": "crossref",
"first-page": "776",
"journal-title": "BMC Infect Dis",
"key": "R20-20260529",
"volume": "22",
"year": "2022"
},
{
"DOI": "10.21037/jtd-24-329",
"article-title": "Opportunity for severe and critical COVID-19 pneumonia treatment with corticosteroids: a retrospective cohort study.",
"author": "Chen",
"doi-asserted-by": "crossref",
"first-page": "5688",
"journal-title": "J Thorac Dis",
"key": "R21-20260529",
"volume": "16",
"year": "2024"
},
{
"DOI": "10.1172/JCI140617",
"article-title": "Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome.",
"author": "Liu",
"doi-asserted-by": "crossref",
"first-page": "6417",
"journal-title": "J Clin Invest",
"key": "R22-20260529",
"volume": "130",
"year": "2020"
},
{
"DOI": "10.1002/hcs2.36",
"article-title": "Diagnosis and treatment protocol for COVID-19 patients (Tentative 10th Version).",
"doi-asserted-by": "crossref",
"first-page": "10",
"journal-title": "Health Care Sci",
"key": "R23-20260529",
"volume": "2",
"year": "2023"
},
{
"DOI": "10.1016/j.amjms.2022.01.022",
"article-title": "COVID-19 and the cardiovascular system: an update.",
"author": "Salabei",
"doi-asserted-by": "crossref",
"first-page": "139",
"journal-title": "Am J Med Sci",
"key": "R24-20260529",
"volume": "364",
"year": "2022"
},
{
"DOI": "10.1016/j.jfma.2024.10.025",
"article-title": "Characteristics and outcomes of ICU-admitted COVID-19 patients in the Omicron and Alpha-dominated periods.",
"author": "Chang",
"doi-asserted-by": "crossref",
"first-page": "413",
"journal-title": "J Formos Med Assoc",
"key": "R25-20260529",
"volume": "124",
"year": "2025"
},
{
"DOI": "10.1016/S0140-6736(23)00510-X",
"article-title": "Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.",
"doi-asserted-by": "crossref",
"first-page": "1499",
"journal-title": "Lancet (Lond)",
"key": "R26-20260529",
"volume": "401",
"year": "2023"
},
{
"DOI": "10.1056/NEJMoa2021436",
"article-title": "Dexamethasone in hospitalized patients with Covid-19.",
"author": "Horby",
"doi-asserted-by": "crossref",
"first-page": "693",
"journal-title": "N Engl J Med",
"key": "R27-20260529",
"volume": "384",
"year": "2021"
},
{
"article-title": "A review on function and side effects of systemic corticosteroids used in high-grade COVID-19 to prevent cytokine storms.",
"author": "Langarizadeh",
"first-page": "339",
"journal-title": "EXCLI J",
"key": "R28-20260529",
"volume": "20",
"year": "2021"
},
{
"DOI": "10.1093/pm/pnaa199",
"article-title": "Corticosteroid injections and COVID-19 infection risk.",
"author": "Miller",
"doi-asserted-by": "crossref",
"first-page": "1703",
"journal-title": "Pain Med",
"key": "R29-20260529",
"volume": "21",
"year": "2020"
},
{
"DOI": "10.1016/j.mayocp.2020.04.006",
"article-title": "Association between hypoxemia and mortality in patients with COVID-19.",
"author": "Xie",
"doi-asserted-by": "crossref",
"first-page": "1138",
"journal-title": "Mayo Clin Proc",
"key": "R30-20260529",
"volume": "95",
"year": "2020"
},
{
"DOI": "10.1097/MD.0000000000041851",
"article-title": "Comparative analysis of demographic, clinical, biochemical, and predictors of mortality in COVID-19 and NON-COVID-19 ARDS patients: a retrospective cohort study.",
"author": "Paulo",
"doi-asserted-by": "crossref",
"first-page": "e41851",
"journal-title": "Medicine (Baltimore)",
"key": "R31-20260529",
"volume": "104",
"year": "2025"
},
{
"DOI": "10.4037/aacnacc2022448",
"article-title": "Silent hypoxia in COVID-19 pneumonia: state of knowledge, pathophysiology, mechanisms, and management.",
"author": "Cajanding",
"doi-asserted-by": "crossref",
"first-page": "143",
"journal-title": "AACN Adv Crit Care",
"key": "R32-20260529",
"volume": "33",
"year": "2022"
},
{
"DOI": "10.1080/15287394.2023.2223598",
"article-title": "Age, gender, and 11 comorbidities as risk factors associated with COVID-19 mortality: a retrospective cohort including 1.8 million individuals.",
"author": "Cruz",
"doi-asserted-by": "crossref",
"first-page": "491",
"journal-title": "J Toxicol Environ Health A",
"key": "R33-20260529",
"volume": "86",
"year": "2023"
},
{
"DOI": "10.1089/vim.2023.0045",
"article-title": "Immunosenescence and Inflammaging in COVID-19.",
"author": "Asghari",
"doi-asserted-by": "crossref",
"first-page": "579",
"journal-title": "Viral Immunol",
"key": "R34-20260529",
"volume": "36",
"year": "2023"
},
{
"DOI": "10.1016/j.arr.2022.101818",
"article-title": "Immunosenescence and inflamm-ageing in COVID-19.",
"author": "Zinatizadeh",
"doi-asserted-by": "crossref",
"first-page": "101818",
"journal-title": "Ageing Res Rev",
"key": "R35-20260529",
"volume": "84",
"year": "2023"
},
{
"DOI": "10.1016/j.pulmoe.2023.01.007",
"article-title": "Risk factors associated with mortality among elderly patients with COVID-19: Data from 55 intensive care units in Spain.",
"author": "Cilloniz",
"doi-asserted-by": "crossref",
"first-page": "362",
"journal-title": "Pulmonology",
"key": "R36-20260529",
"volume": "29",
"year": "2023"
},
{
"DOI": "10.4235/agmr.23.0105",
"article-title": "The risk factors of COVID-19 infection and mortality among older adults in South Korea.",
"author": "Lee",
"doi-asserted-by": "crossref",
"first-page": "241",
"journal-title": "Ann Geriatr Med Res",
"key": "R37-20260529",
"volume": "27",
"year": "2023"
},
{
"article-title": "Prevalence and prognostic value of cardiac troponin in elderly patients hospitalized for COVID-19.",
"author": "De Marzo",
"first-page": "338",
"journal-title": "J Geriatr Cardiol",
"key": "R38-20260529",
"volume": "18",
"year": "2021"
},
{
"DOI": "10.7150/ijms.53641",
"article-title": "Cardiac troponin I association with critical illness and death risk in 726 seriously ill COVID-19 patients: a retrospective cohort study.",
"author": "Chen",
"doi-asserted-by": "crossref",
"first-page": "1474",
"journal-title": "Int J Med Sci",
"key": "R39-20260529",
"volume": "18",
"year": "2021"
},
{
"DOI": "10.1016/j.hfc.2022.08.005",
"article-title": "Use and prognostic implications of cardiac troponin in COVID-19.",
"author": "De Michieli",
"doi-asserted-by": "crossref",
"first-page": "163",
"journal-title": "Heart Fail Clin",
"key": "R40-20260529",
"volume": "19",
"year": "2023"
},
{
"DOI": "10.1161/CIRCRESAHA.123.321876",
"article-title": "Cell-specific mechanisms in the heart of COVID-19 patients.",
"author": "Tsai",
"doi-asserted-by": "crossref",
"first-page": "1290",
"journal-title": "Circ Res",
"key": "R41-20260529",
"volume": "132",
"year": "2023"
},
{
"DOI": "10.1007/s11897-023-00618-w",
"article-title": "Mechanism of COVID-19-induced cardiac damage from patient, in vitro and animal studies.",
"author": "Jones",
"doi-asserted-by": "crossref",
"first-page": "451",
"journal-title": "Curr Heart Fail Rep",
"key": "R42-20260529",
"volume": "20",
"year": "2023"
},
{
"DOI": "10.1161/CIRCULATIONAHA.120.048789",
"article-title": "Cardiac troponin I is an independent predictor for mortality in hospitalized patients with COVID-19.",
"author": "Nie",
"doi-asserted-by": "crossref",
"first-page": "608",
"journal-title": "Circulation",
"key": "R43-20260529",
"volume": "142",
"year": "2020"
}
],
"reference-count": 42,
"references-count": 42,
"relation": {},
"resource": {
"primary": {
"URL": "https://journals.lww.com/10.1097/MD.0000000000049099"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"title": "Independent mortality predictors in older COVID-19 patients with delayed hospitalization: A retrospective study from Eastern China, 2023",
"type": "journal-article",
"update-policy": "https://doi.org/10.1097/lww.0000000000001000",
"volume": "105"
}
Late treatment
is less effective
is less effective
